scanance.
Sign inGet Premium
OS

OraSure Technologies, Inc.

OSURHealthcareNASDAQ

Medical Instruments & Supplies

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$115.0M
-38.1% YoY
Net Income
-$68.7M
-252.5% YoY
EBITDA
-$58.2M
-329.2% YoY
Free Cash Flow
-$8.9M

Scan Results

Daily timeframe
DateIndicatorDetails
Loading...
About OraSure Technologies, Inc.

OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products and specimen collection devices in the United States, Europe,. At a $287.8M market cap, OraSure Technologies, Inc. ranks as a micro-cap company within healthcare. It offers OraQuick Rapid HIV test, OraQuick HIV self-test, OraQuick HIV self-test(international), OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, SickleSCAN test, and OraSure oral fluid collection device for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.

Key stats
Market Cap$287.8M
Fwd P/E-8.31
EPS$-1.05
Beta1.01
52W Change+45.1%
ROE-21.2%
Analysis

OraSure Technologies, Inc. holds $177.0M in cash against $12.7M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$8.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -21.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $387.5M (2022) to $115.0M (2025), a 70% decline worth watching.

The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for OraSure Technologies, Inc. and its sector.

Links
Not financial advice. Scanance is an educational tool. Past performance does not guarantee future results.PrivacyTerms